The abstract is read at the publisher; the summary is JClub's.
Sidetrak, a 36-amino-acid miniprotein, binds kinesin-1 with nanomolar affinity and disrupts MAP7 binding by targeting the kinesin-1 coiled-coil TDS interface.
- Why it matters: MAP7 regulates kinesin-1 by binding a coiled-coil surface overlapping the TPR docking site, but this regulatory interface has been largely unexploited for selective intracellular transport control.
- What they did: Using an AlphaFold3 model and BoltzGen, the authors designed Sidetrak and tested whether binding depends on the TDS, then measured effects on MAP7 recruitment, mitochondrial positioning, and kinesin-1 paralog binding.
- The result: Sidetrak inhibits MAP7 binding, reduces MAP7-dependent kinesin-1 recruitment to microtubules in cells, and causes perinuclear mitochondrial redistribution, while selectively associating with endogenous kinesin-1 complexes and cargo adaptors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.